SNS-062: Preliminary Phase Ia data

Preliminary data from a double-blind, placebo-controlled, Belgian Phase Ia trial in 32 healthy volunteers showed that single doses of 50, 100, 200 and 300 mg oral SNS-062 led to no serious adverse eve...